Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines

The Journal of surgical research - 1 Jun 2020

Teraoka Saeko, Muguruma Masako, Takano Naoharu, Miyahara Kana, Kawate Takahiko, Kaise Hiroshi, Yamada Kimito, Miyazawa Keisuke, Ishikawa Takashi

Abstract excerpt

BACKGROUND: Many triple-negative breast cancers (TNBCs) show impaired breast cancer susceptibility gene I (BRCA1) function, called BRCAness. BRCAness tumors may show similar sensitivities to anticancer drugs as tumors with BRCA1 mutations. In this study, we investigated the association of BRCA mutations or BRCAness with drug sensitivities in TNBC. METHODS: BRCAness was evaluated as BRCA1-like scores, using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Cisplatin

Share to Docetaxel

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 32092597
DOI: 10.1016/j.jss.2019.12.040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell LinesPMID 32092597Read ↗

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Semantic proximity Read ↗

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.Semantic proximity Read ↗

BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.Semantic proximity Read ↗

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.Semantic proximity Read ↗

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Semantic proximity Read ↗

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.Semantic proximity Read ↗

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair DeficiencySemantic proximity Read ↗

Activity Of Docetaxel, Carboplatin, And Doxorubicin In Patient-Derived Triple-Negative Breast Cancer Xenografts Semantic proximity Read ↗

BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxaneSemantic proximity Read ↗

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.Semantic proximity Read ↗

A Targeted RNAi Screen of the Breast Cancer Genome Identifies <i>KIF14</i> and <i>TLN1</i> as Genes That Modulate Docetaxel Chemosensitivity in Triple-Negative Breast CancerSemantic proximity Read ↗

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.